^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

MMP2 (Matrix metallopeptidase 2)

i
Other names: MMP2, CLG4, CLG4A, TBE-1, Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)
3d
Dual inhibition of MMP-2 and actin dynamics by a novel bis-chalcone: an anticancer strategy for oral squamous cell carcinoma. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
Molecular docking indicated MMP-2 and F-actin affinity, and was corroborated by molecular assays confirming protein modulation for both. Our findings identify B2OCH3 as a promising therapeutic candidate for OSCC, highlighting its potential to simultaneously target both MMP-2 activity and actin cytoskeleton regulation.
Journal
|
MMP2 (Matrix metallopeptidase 2)
3d
Anticancer effect of palmitoyl piperidinopiperidine against human pancreatic ductal adenocarcinoma cells. (PubMed, Cancer Genet)
These results suggest that PPI exerts antitumor effects against BxPC-3 cells by inhibiting STAT3 phosphorylation.
Journal
|
CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • MMP2 (Matrix metallopeptidase 2) • CDK2 (Cyclin-dependent kinase 2) • MMP9 (Matrix metallopeptidase 9)
4d
Bioinformatic Analysis of Contrasting Expression Patterns and Molecular Interactions of TIMPs in Breast Cancer: Implications for Tumor Progression and Survival. (PubMed, Pathophysiology)
TIMPs display contrasting expression profiles and distinct pathway associations in breast cancer. TIMP1 emerges as the only consistently overexpressed inhibitor, while TIMP4 appears as a promising prognostic marker with unique MMP correlations that may influence tumor behaviors.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • MMP2 (Matrix metallopeptidase 2) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • MMP9 (Matrix metallopeptidase 9) • MMP1 (Matrix metallopeptidase 1) • ADAM10 (ADAM Metallopeptidase Domain 10) • ADAM12 (ADAM Metallopeptidase Domain 12) • ADAM15 (ADAM Metallopeptidase Domain 15) • MMP14 (Matrix Metallopeptidase 14) • TIMP3 (TIMP Metallopeptidase Inhibitor 3)
4d
M2 macrophage-derived extracellular vesicles induce EMT-like transcriptional reprogramming in colorectal cancer cells via upregulation of FAM83A. (PubMed, Sci Rep)
Importantly, siRNA-mediated silencing of FAM83A abolished its overexpression and inhibited EMT activation, confirming its essential role in M2-Exo-induced programming of EMT. Collectively, these findings highlight exosome-mediated immune-tumor interactions as critical drivers of EMT and the progression toward an invasive, mesenchymal-like phenotype.
Journal
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9)
4d
Nanoplex cluster-mediated synergistic modulation of dendritic cells and T cells amplifies tumor-specific adaptive immunity. (PubMed, Biomaterials)
The formulation comprises a nanoplex (NP) encapsulating CpG ODN 1826 (CpG NP), which stimulates TLR-9 and elevates the levels of CD80/86 costimulatory molecules on antigen-presenting cells, and a NP incorporating CTLA-4 siRNA (siCTLA-4 NP), which suppresses the production of the immunological checkpoint molecule CTLA-4 on T cells...Ex-vivo study of cell composition in spleens and tumors, along with tumor-specific antigen stimulation assays on splenocytes, suggests that NC treatment can switch the immunosuppressive tumor microenvironment into an immunocompetent state. These findings demonstrate that our NC formulation, which integrates CTLA-4 suppression with DC stimulation, potentiates immune responses against tumor tissues, providing novel insights and potential applications in the field of cancer immunotherapy.
Journal
|
MMP2 (Matrix metallopeptidase 2) • TLR9 (Toll Like Receptor 9) • CD80 (CD80 Molecule)
5d
Mapping metastatic potential through cytoskeletal remodeling: A mechanobiology-based multi-cancer analysis. (PubMed, Biochem Biophys Res Commun)
Unlike conventional markers that often reflect tumor-specific traits, this panel captures the mechanical and structural determinants of cell invasiveness. The robustness of these genes across diverse molecular assays and their alignment with core metastatic pathways underscore their translational relevance.
Journal
|
CDH1 (Cadherin 1) • EPCAM (Epithelial cell adhesion molecule) • MMP2 (Matrix metallopeptidase 2) • FSCN1 (Fascin Actin-Bundling Protein 1)
6d
Encapsulation of hydroxyurea in exosomes derived from adipose mesenchymal stem cells enhances anticancer efficacy in breast cancer. (PubMed, Transl Oncol)
These results suggest that exosomes improve drug uptake and bypass drug resistance mechanisms, enabling dose reduction and minimizing side effects. This study introduces HU-Exo as a targeted and multifaceted drug delivery system capable of inhibiting breast tumor growth and metastasis, paving the way for the development of novel and combination therapies in the future.
Journal
|
MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
hydroxyurea
7d
Targeting of HSP27 and MMP-2/9 Crosstalk by High-Throughput Drug Repurposing Strategies Identifies Paroxetine as a Potential Candidate in Glioblastoma. (PubMed, J Med Chem)
The C6 glioma rat model further confirmed the suppression of HSP27 and its crosstalk partner MMP-2/9 in tumor tissue. Collectively, these findings establish paroxetine as a functional HSP27 inhibitor that disrupts the interaction between HSP27 and MMP-2/9, thereby inhibiting glioblastoma progression.
Journal
|
MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
10d
Targeting PDK4 attenuates neointimal hyperplasia and regulates VSMC phenotypic Switching, Apoptosis, and autophagy. (PubMed, Biochem Pharmacol)
In vivo, perivascular delivery of PDK4-IN-1 in the mouse carotid artery injury model significantly ameliorated neointimal hyperplasia. Inhibition of PDK4 perturbs pathological VSMC phenotypic switching, suppresses proliferation, promotes apoptosis and autophagy, and mitigates neointimal formation, highlighting PDK4 as a promising therapeutic target for vascular proliferative diseases.
Journal
|
MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • LAMP1 (Lysosomal Associated Membrane Protein 1) • MMP9 (Matrix metallopeptidase 9) • PDK4 (Pyruvate Dehydrogenase Kinase 4) • ANXA5 (Annexin A5) • ATG7 (Autophagy Related 7) • BECN1 (Beclin 1)
10d
Cordycepin inhibits human extravillous trophoblast invasion by suppressing snail-mediated MMP2 expression. (PubMed, Tissue Cell)
Functionally, COR treatment inhibited EVT cell invasion, and this effect was mediated by MMP2 downregulation. These findings provide new insights into the molecular mechanisms by which COR regulates EVT cell invasiveness and highlight the potential implications of COR as a health supplement during pregnancy.
Journal
|
MMP2 (Matrix metallopeptidase 2)
|
cordycepin (OVI-123)
10d
Synergistic anticancer effects of tamoxifen in combination with fisetin and chrysin on breast cancer cells: insights into viability, migration, and apoptosis. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
Furthermore, co-treatment markedly downregulated MMP2 and MMP9 expression. Collectively, these findings demonstrate that fisetin and chrysin enhance the anticancer efficacy of tamoxifen through synergistic mechanisms in breast cancer cells.
Journal
|
ER (Estrogen receptor) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
ER positive
|
tamoxifen
11d
The metastasis landscape of Clonorchis sinensis-associated hepatocellular carcinoma: an integrated multi-omics and clinical study. (PubMed, Front Immunol)
Molecular experiments further demonstrated that Cs infection enhances the metastatic potential of HCC. Our study reveals that Cs infection promotes HCC metastasis through gene and epigenetic alterations, providing mechanistic insights and identifying potential targets for early intervention.
Retrospective data • Journal
|
SPP1 (Secreted Phosphoprotein 1) • MMP2 (Matrix metallopeptidase 2) • VCAM1 (Vascular Cell Adhesion Molecule 1)